Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy

Immunotherapy

Volumn 6, Issue 7, 2014, Pages 803-805

  Savas, Peter ^a   Loi, Sherene ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

adjuvant; anti PD 1; breast cancer; HER2; trastuzumab; tumor infiltrating lymphocytes

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ART; BREAST NEOPLASMS; CELLULAR IMMUNITY; FEMALE; IMMUNOLOGY; LYMPHOCYTE; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTES; PORTRAITS AS TOPIC;

EID: 84907814800     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.60     Document Type: Review

References (17)

1. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc. Natl Acad. Sci. USA 109(8), 2796-2801 (2012
2. Gu-Trantien C, Loi S, Garaud S et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123(7), 2873-2892 (2013
3. Mahmoud SMA, Paish EC, Powe DG et al. Tumorinfiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29(15), 1949-1955 (2011
4. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31(7), 860-867 (2013
5. Denkert C, Loibl S, Noske A et al. Tumor-Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28(1), 105-113 (2010
6. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71(14), 4809-4820 (2011
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005
8. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001
9. Park S, Jiang Z, Mortenson ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18(2), 160-170 (2010
10. Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti- PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108(17), 7142-7147 (2011
11. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHER Trial. J. Clin. Oncol. 27(34), 5685-5692 (2009
12. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25(8), 1544-1550 (2014
13. Denkert C, Loibl S, Salat C et al. Increased tumor-Associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Presented at: San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, 10-14 December 2013
14. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
15. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
16. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
17. Wang Q, Li S-H, Wang H et al. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 72(17), 4417-4428 (2012